Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus Target Price from Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $3.75.

HOWL has been the topic of several research analyst reports. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research report on Friday, December 19th. HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $0.57, for a total transaction of $33,618.60. Following the completion of the transaction, the director owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. This represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders sold 5,827,036 shares of company stock worth $6,194,385. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently modified their holdings of the business. Susquehanna International Group LLP raised its position in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the period. Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter valued at approximately $304,000. Vanguard Group Inc. raised its holdings in Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the period. Bridgeway Capital Management LLC lifted its position in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $0.67 on Friday. The business’s 50 day simple moving average is $0.78 and its 200 day simple moving average is $1.21. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The stock has a market capitalization of $32.75 million, a PE ratio of -0.42 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, research analysts forecast that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.